• Something wrong with this record ?

BDNF secretion by human pulmonary artery endothelial cells in response to hypoxia

M. Helan, B. Aravamudan, WR. Hartman, MA. Thompson, BD. Johnson, CM. Pabelick, YS. Prakash,

. 2014 ; 68 (-) : 89-97.

Language English Country England, Great Britain

Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Within human pulmonary artery, neurotrophin growth factors [NTs; e.g. brain-derived neurotrophic factor (BDNF)] and their high-affinity receptors (tropomyosin-related kinase; Trk) and low-affinity receptors p75 neurotrophin receptor (p75NTR) have been reported, but their functional role is incompletely understood. We tested the hypothesis that BDNF is produced by human pulmonary artery endothelial cells (PAECs). In the context of hypoxia as a risk factor for pulmonary hypertension, we examined the effect of hypoxia on BDNF secretion and consequent autocrine effects on pulmonary endothelium. Initial ELISA analysis of circulating BDNF in 30 healthy human volunteers showed that 72 h exposure to high altitude (~11,000 ft, alveolar PO2 = 100 mmHg) results in higher BDNF compared to samples taken at sea level. Separately, in human PAECs exposed for 24h to normoxia vs. hypoxia (1-3% O2), ELISA of extracellular media showed increased BDNF levels. Furthermore, quantitative PCR of PAECs showed 3-fold enhancement of BDNF gene transcription with hypoxia. In PAECs, BDNF induced NO production (measured using an NO-sensitive fluorescent dye DAF2-DA) that was significantly higher under hypoxic conditions, an effect also noted with the TrkB agonist 7,8-DHF. Importantly, hypoxia-induced NO was blunted by neutralization of secreted BDNF using the chimeric TrkB-Fc. Both hypoxia and BDNF increased iNOS (but not eNOS) mRNA expression. In accordance, BDNF enhancement of NO in hypoxia was not blunted by 50 nM L-NAME (eNOS inhibition) but substantially lower with 100 μM L-NAME (eNOS and iNOS inhibition). Hypoxia and BDNF also induced expression of hypoxia inducible factor 1 alpha (HIF-1α), a subunit of the transcription factor HIF-1, and pharmacological inhibition of HIF-1 diminished hypoxia effects on BDNF expression and secretion, and NO production. These results indicate that human PAECs express and secrete BDNF in response to hypoxia via a HIF-1-regulated pathway.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15008373
003      
CZ-PrNML
005      
20150327115222.0
007      
ta
008      
150306s2014 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.yjmcc.2014.01.006 $2 doi
035    __
$a (PubMed)24462831
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Helan, Martin $u Department of Anesthesiology, Mayo Clinic, Rochester, USA; ICRC, International Clinical Research Center, Brno, Czech Republic; Department of Anesthesiology and Intensive Care, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
245    10
$a BDNF secretion by human pulmonary artery endothelial cells in response to hypoxia / $c M. Helan, B. Aravamudan, WR. Hartman, MA. Thompson, BD. Johnson, CM. Pabelick, YS. Prakash,
520    9_
$a Within human pulmonary artery, neurotrophin growth factors [NTs; e.g. brain-derived neurotrophic factor (BDNF)] and their high-affinity receptors (tropomyosin-related kinase; Trk) and low-affinity receptors p75 neurotrophin receptor (p75NTR) have been reported, but their functional role is incompletely understood. We tested the hypothesis that BDNF is produced by human pulmonary artery endothelial cells (PAECs). In the context of hypoxia as a risk factor for pulmonary hypertension, we examined the effect of hypoxia on BDNF secretion and consequent autocrine effects on pulmonary endothelium. Initial ELISA analysis of circulating BDNF in 30 healthy human volunteers showed that 72 h exposure to high altitude (~11,000 ft, alveolar PO2 = 100 mmHg) results in higher BDNF compared to samples taken at sea level. Separately, in human PAECs exposed for 24h to normoxia vs. hypoxia (1-3% O2), ELISA of extracellular media showed increased BDNF levels. Furthermore, quantitative PCR of PAECs showed 3-fold enhancement of BDNF gene transcription with hypoxia. In PAECs, BDNF induced NO production (measured using an NO-sensitive fluorescent dye DAF2-DA) that was significantly higher under hypoxic conditions, an effect also noted with the TrkB agonist 7,8-DHF. Importantly, hypoxia-induced NO was blunted by neutralization of secreted BDNF using the chimeric TrkB-Fc. Both hypoxia and BDNF increased iNOS (but not eNOS) mRNA expression. In accordance, BDNF enhancement of NO in hypoxia was not blunted by 50 nM L-NAME (eNOS inhibition) but substantially lower with 100 μM L-NAME (eNOS and iNOS inhibition). Hypoxia and BDNF also induced expression of hypoxia inducible factor 1 alpha (HIF-1α), a subunit of the transcription factor HIF-1, and pharmacological inhibition of HIF-1 diminished hypoxia effects on BDNF expression and secretion, and NO production. These results indicate that human PAECs express and secrete BDNF in response to hypoxia via a HIF-1-regulated pathway.
650    _2
$a hypoxie $x krev $7 D000860
650    _2
$a arginasa $x metabolismus $7 D001119
650    _2
$a mozkový neurotrofický faktor $x krev $x genetika $x sekrece $7 D019208
650    _2
$a hypoxie buňky $7 D015687
650    _2
$a kultivované buňky $7 D002478
650    _2
$a endoteliální buňky $x metabolismus $x sekrece $7 D042783
650    _2
$a cévní endotel $x patologie $7 D004730
650    _2
$a exprese genu $7 D015870
650    _2
$a lidé $7 D006801
650    _2
$a faktor 1 indukovatelný hypoxií $x metabolismus $7 D051793
650    _2
$a oxid dusnatý $x metabolismus $7 D009569
650    _2
$a synthasa oxidu dusnatého, typ II $x metabolismus $7 D052247
650    _2
$a synthasa oxidu dusnatého, typ III $x metabolismus $7 D052250
650    _2
$a proteinkinasy $x metabolismus $7 D011494
650    _2
$a arteria pulmonalis $x patologie $7 D011651
650    _2
$a messenger RNA $x genetika $x metabolismus $7 D012333
650    _2
$a signální transdukce $7 D015398
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Aravamudan, Bharathi $u Department of Anesthesiology, Mayo Clinic, Rochester, USA. $7 gn_A_00008046
700    1_
$a Hartman, William R $u Department of Anesthesiology, Mayo Clinic, Rochester, USA; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, USA.
700    1_
$a Thompson, Michael A $u Department of Anesthesiology, Mayo Clinic, Rochester, USA.
700    1_
$a Johnson, Bruce D $u Department of Medicine, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, USA.
700    1_
$a Pabelick, Christina M $u Department of Anesthesiology, Mayo Clinic, Rochester, USA; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, USA.
700    1_
$a Prakash, Y S $u Department of Anesthesiology, Mayo Clinic, Rochester, USA; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, USA. Electronic address: Prakash.ys@mayo.edu.
773    0_
$w MED00002807 $t Journal of molecular and cellular cardiology $x 1095-8584 $g Roč. 68, č. - (2014), s. 89-97
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24462831 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150306 $b ABA008
991    __
$a 20150327115544 $b ABA008
999    __
$a ok $b bmc $g 1065646 $s 891173
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 68 $c - $d 89-97 $i 1095-8584 $m Journal of Molecular and Cellular Cardiology $n J Mol Cell Cardiol $x MED00002807
LZP    __
$a Pubmed-20150306

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...